2016 European PRRS Research Award: Boehringer Ingelheim Animal Health calls for submissions until July 1^st

Ingelheim, Germany, 15 March 2016 – For the third time, Boehringer Ingelheim Animal Health sponsors the European PRRS Research Award to support applied research for improved control of the swine disease PRRS (Porcine Reproductive and Respiratory Syndrome). Research proposals for the 2016 European PRRS Research Award can be submitted until July 1st, 2016. Boehringer Ingelheim Animal Health will provide three grants of 25,000 euros each to fund research proposals that will generate new and relevant data to better understand this devastating and costly disease.

The European PRRS Research Award aims at encouraging research, which eventually results in practical application strategies to control PRRS and enhances the interaction among swine researchers and veterinarians. In addition, Boehringer Ingelheim Animal Health’s intention is to further stimulate communication in the industry on practical PRRS control strategies and to reward research excellence. The PRRS virus infects pigs around the globe causing respiratory tract illness in growing pigs and reproductive failure in breeding stock; Boehringer Ingelheim Animal Health strives to find solutions for sustainable PRRS control.

Applications to submit research proposals can be made online via www.prrs.com. An independent review board will assess each proposal carefully. Members of the review board are highly recognized swine industry professionals including researchers and practitioners. The board will select proposals based on several factors, including their significance, potential for impact to the swine industry, originality and innovation. 

The winners of this year’s European PRRS Research Award will be announced in September 2016. 

For more information please visit www.prrs.com 

About Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health is the 6th largest animal health business in the world and is committed to providing leading innovative solutions to prevent, treat and cure animal diseases. With approximately 4,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about € 1.13 billion in 2014. Main brands of Boehringer Ingelheim’s Animal Health portfolio are Ingelvac Circoflex^® (2014 sales of € 260 million), Metacam^® (2014 sales of € 93 million), Ingelvac PRRS^® (2014 sales of € 74 million), Duramune^® (2014 sales of € 69 million) and Vetmedin^® (2014 sales of € 57 million), representing 8% of the corporation’s revenue base. From a regional perspective, Boehringer Ingelheim has its legacy as an Animal Health company in the US with most of its R&D and manufacturing infrastructure located there. Significant investments have been made recently in Hanover, Germany and are underway in China. The Boehringer Ingelheim Animal Health Business is currently holding strong positions in swine and cattle vaccines as well as in pharmaceutical specialties for animal use. In its research-driven Animal Health business, Boehringer Ingelheim continually invests more than 12% of net sales of the Animal Health business in R&D.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.